Advanced

Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls

Emmerich, Joseph; Rosendaal, Frits R.; Cattaneo, Marco; Margaglione, Maurizio; De Stefano, Valerio; Cumming, Tony; Arruda, Valder; Hillarp, Andreas LU and Reny, Jean-Luc (2001) In Thrombosis and Haemostasis 86(3). p.809-816
Abstract
Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% Cl; 4.1-5.9) for the factor V Leiden and 3.8 (3.0-4.9) for the factor II G20210A mutation. Fifty-one cases (2.2%,) and none of the controls were double heterozygotes. The odds ratio for venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). Twelve percent of patients heterozygous for factor V Leiden were also heterozygous for factor II G20210A and conversely 23%... (More)
Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% Cl; 4.1-5.9) for the factor V Leiden and 3.8 (3.0-4.9) for the factor II G20210A mutation. Fifty-one cases (2.2%,) and none of the controls were double heterozygotes. The odds ratio for venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). Twelve percent of patients heterozygous for factor V Leiden were also heterozygous for factor II G20210A and conversely 23% of patients heterozygous for factor II G20210A were also heterozygous for factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptive (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In factor V Leiden carriers using OC, die odds ratio for VTE was 10.25 18.45). The odds ratio of the association of factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of factor V Leiden was lower in patients with pulmonary embolism than in patients with deep vein thrombosis without PE (odds ratio 0.69). Conversely, factor II G20210A mutation was equally balanced in both patient groups. (Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
in
Thrombosis and Haemostasis
volume
86
issue
3
pages
809 - 816
publisher
F K Schattauer Verlag Gmbh
external identifiers
  • wos:000170992600014
  • scopus:0034840147
ISSN
0340-6245
language
English
LU publication?
no
id
ec9c5fd6-dbcd-4c64-be77-0e92a7be693f (old id 1118919)
date added to LUP
2008-06-26 15:56:57
date last changed
2018-10-03 11:56:13
@article{ec9c5fd6-dbcd-4c64-be77-0e92a7be693f,
  abstract     = {Factor V Leiden and factor II G20210A mutations are two frequent genetic risk factors involved in venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% Cl; 4.1-5.9) for the factor V Leiden and 3.8 (3.0-4.9) for the factor II G20210A mutation. Fifty-one cases (2.2%,) and none of the controls were double heterozygotes. The odds ratio for venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). Twelve percent of patients heterozygous for factor V Leiden were also heterozygous for factor II G20210A and conversely 23% of patients heterozygous for factor II G20210A were also heterozygous for factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptive (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In factor V Leiden carriers using OC, die odds ratio for VTE was 10.25 18.45). The odds ratio of the association of factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of factor V Leiden was lower in patients with pulmonary embolism than in patients with deep vein thrombosis without PE (odds ratio 0.69). Conversely, factor II G20210A mutation was equally balanced in both patient groups.},
  author       = {Emmerich, Joseph and Rosendaal, Frits R. and Cattaneo, Marco and Margaglione, Maurizio and De Stefano, Valerio and Cumming, Tony and Arruda, Valder and Hillarp, Andreas and Reny, Jean-Luc},
  issn         = {0340-6245},
  language     = {eng},
  number       = {3},
  pages        = {809--816},
  publisher    = {F K Schattauer Verlag Gmbh},
  series       = {Thrombosis and Haemostasis},
  title        = {Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls},
  volume       = {86},
  year         = {2001},
}